A Phase 3 interventional study of JP-1366 20mg and Lansoprazole 30mg in Gastric Ulcer, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.
Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Stomach Ulcer with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Stomach Ulcer · Korea, Republic of.
Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 15th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →2 of the 20 studies in Stomach Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of, Indonesia
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 329 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 199 across the 17 interventional studies, 60 across the 3 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Onconic Therapeutics Inc., one of the names counted as Jeil Pharmaceutical Co., Ltd.. Under that name alone:
Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Jeil Pharmaceutical Co., Ltd. has 1 study filed under Stomach Ulcer — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer
Inclusion Criteria: Subjects who meet all of the following criteria can participate in this study:
Confirmation via upper gastrointestinal endoscopy within 14 days from Visit 2 for the following:
º One or more GUs with the largest ulcer ≥ 3 mm to ≤ 30 mm
º Largest ulcer classified as A1 or A2 based on Sakita-Miwa classification
[Medical History]
Subjects who have had or are scheduled to have major surgery that may affect gastric acid secretion within 30 days from Visit 1
[Comorbidity]
Subjects who confirmed malignant tumors by upper gastrointestinal endoscopy during the Screening (Visit 1). If a is required. Subject who may have an impact on the lesion evaluated in this clinical trial needs to be excluded, and the biopsy should not be delayed for registration in this clinical trial.
[Drug Dosing/Treatment History]
Subjects with a history of taking any of the following drugs or those required to take them until the end of treatment (EOT): For participation in this trial, stable drugs must not be discontinued.:
\<Drugs prohibited from within 2 weeks of Visit 1 to EOT>
º All acid blockers other than the IPs: H2 receptor antagonists, proton pump inhibitors (PPIs) and potassium-competitive gastric acid blockers
º Gastromucosal protection agents: Prostaglandins (however, local administration is allowed) and mucosal blood flow stimulants Antacids
º Gastrointestinal motility stimulants
º Anticholinergics (however, local administration is allowed)
º Cholinergic agents (however, local administration is allowed)
º Glucocorticosteroids (however, local administration is allowed)
º Gastrin receptor antagonist, other drugs for the treatment of peptic ulcer
\<Drugs prohibited from Visit 1 to EOT>
º Rilpivirine, atazanavir, and nelfinavir
º Antipsychotics, antidepressants, and antianxiety drugs
\<1 week prior to the date of upper gastrointestinal endoscopy(EGD)>
º Non-steroidal anti-inflammatory drugs (NSAIDs)
º Antithrombotic agents: Anticoagulants or antiplatelet drugs
However, among the above drugs, drugs administered as a pre-treatment for upper gastrointestinal endoscopy or for an urea breath test are allowed
: midazolam, propofol, simethicone, hyoscine butylbromide, cimetropium bromide, magmil, pethidine, gasocol, urea, etc.
Subjects who have clinically significant abnormal
[Laboratory Tests]
Blood test results meet the criteria below at Visit 1:
º , AST, ALP, GGT, Total > 2.0 x
º \< 60 mL/min/1.73 m2
[Other]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: JP-1366 20mg
Drug: Lansoprazole 30mg
JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy by Week 8
Time frame: Week 8
Complete healing rate for ulcers confirmed by upper gastrointestinal endoscopy at Week 4
Time frame: Week 4
Complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy at Week 4 by Helicobacter pylori infection status
Time frame: Week 4
Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy according to Helicobacter pylori infection status by Week 8
Time frame: Week 8
Changes of Gastrointestinal symptoms per NDI-K at week 4 and 8
The frequency and severity of 15 gastointestinal symptoms were scored on a scale from 0 to 4 using a score sheet.
Time frame: Week 4 and 8
Changes in quality of life (EQ-5D-5L) at Weeks 4 and 8
Time frame: Week 4 and 8
Changes and the proportion of changes of the ulcer size(s) at week 4 and week 8
Subjects will also rate their health status on the visual analogue scale (VAS) between 0 (the worst state) and 100 (the best state) to get the score for their overall health.
Time frame: Week 4 and 8
Change of the number of ulcer(s) at week 4 and week 8
Time frame: Week 4 and 8
Exploratory Endpoints
Blood Gastrin Test
Time frame: 2weeks after the end of treatment
Ran from Sep 2022 to primary completion in Jul 2024, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zastaprazan